LLY250110C760000
- 27.00
- +10.95+68.22%
Eli Lilly and Co Newsroom
Medicare Expands Coverage of Eli Lilly's Weight-Loss Drug -- WSJ
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Zentalis Pharma Says FDA Grants Fast Track Status on Azenosertib Cancer Drug Candidate
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Medicare Can Cover Zepbound for Sleep Apnea, Creating a Significant Opportunity for Eli Lilly
Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge -- Barrons.com
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
LLY Falls Around 14% in 3 Months: How to Play the Stock
Express News | Eli Lilly - New Centre Expected to Open in Mid-2025
Express News | Lilly - to Establish New Global Capability Centre in Hyderabad, India
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Express News | CMS: With FDA Approved Use for Zepbound to Treat Obstructive Sleep Apnea, Current Medicare Part D and Medicaid Coverage Rules Apply
'Medicare Can Now Cover Eli Lilly's Zepbound For Sleep Apnea, CMS Says' - CNBC
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Novo Nordisk Needs Answers to These 5 Key Questions
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
What Trump's Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
FDA Issues Draft Guidance on Developing Weight Loss Drugs